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Abstract
Objectives The aim of this study was to evaluate the effect
of limb malformations on health-related quality of life
(HRQL) and function of the extremities in middle-aged
individuals with thalidomide embryopathy (TE). Between
1959 and 1962, approximately 150 children with multiple
malformations were born in Sweden following the mater-
nal intake of thalidomide during pregnancy, of whom 100
survived.
Methods Thirty-one individuals with TE underwent eval-
uations of musculoskeletal manifestations by clinical
examination. Validated questionnaires were used for the
assessment of general HRQL [the 36-Item Short Form
Health Survey (SF-36) and the EuroQ Five Dimensions
health questionnaire (EQ-5D)]. The function of the upper
and lower extremities was evaluated using specific ques-
tionnaires (Disabilities of the Arm, Shoulder and Hand
scale and Rheumatoid and Arthritis Outcome Score,
respectively). The lower limbs were evaluated by com-
puted tomography. The median age of the study group was
46 years, and 42% were females. Twenty-five individuals
had malformations of the hand, but 27 had a grip function.
Five individuals had severe lower limb malformations.
Individuals with at least one extremity with major mal-
formation(s) that affected function (n = 15) were com-
pared with those without (n = 16).
Results The physical HRQL for the entire study group
[mean 40.6, 95% confidence interval (CI) 35.4–45.8], as
evaluated by the Physical Composite Score (PCS) of the
SF-36, was significantly lower than the national norm value
(population-based norm) of 50.0, and the physical HRQL
of the subgroup with major limb malformations (15/31)
was even lower (mean 34.6, 95% CI 25.9–43.4). The
mental aspects of HRQL, based on SF-36 and EQ-5D
scores, were not affected in the entire study group or in the
subgroups.
Conclusion The physical quality of life was significantly
lower in individuals with TE compared with the general
national population, while the mental aspects were not
affected.
Level of evidence IV.
Keywords Thalidomide  Embryopathy  Long term 
Outcome  Function  Quality of life
Introduction
Children with congenital or acquired conditions are forced
to learn to manage their situation from the very beginning.
Sometimes, despite treatment or surgical procedures, they
enter adult life with functional deficiencies that will last
their entire life. With aging, there is a risk of deterioration
due to the development of degenerative changes. An
individual with acceptable performance in early adulthood
may have been on the border of his/her ability, but, with
aging, this ability might be lost.
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Over the years, thalidomide has been used to treat dif-
ferent medical conditions, such as leprosy and other painful
conditions [1]. In the late 1950s and the beginning of the
1960s, thalidomide was offered as a treatment for insomnia
and was frequently used by pregnant women due to its
reputation of being harmless. However, when the number
of children born with multiple malformations all over the
world increased following the maternal intake of thalido-
mide during pregnancy [2, 3], it gradually became apparent
that thalidomide was a highly teratogenic substance [4].
This led to the syndrome being referred to as thalidomide
embryopathy (TE). Thalidomide was subsequently banned
from the market for some years, but today it is once again
being used for the treatment of leprosy [5, 6], multiple
myeloma [7], Crohn’s disease [8], and other conditions.
Despite our knowledge of the teratogenic effect of
thalidomide, children still being born with TE [6]. Infor-
mation on its teratogenic effects is still insufficient and
action for the prevention of TE is not being taken.
Malformations induced by thalidomide include those
affecting the ears, eyes, oral region, musculoskeletal sys-
tem, and a variety of inner organs [9]. There is large
individual variation in terms of the number and the severity
of these malformations, and some children die before
reaching adulthood. The malformations that do occur are
not specific to TE, and all malformations can occur sepa-
rately without any previous use of thalidomide. Informa-
tion on the long-term outcome of individuals with major
malformations, and especially on the long-term outcome of
those with TE, is relatively scarce.
The children with TE born at the beginning of the 1960s
have now reached middle age. Some studies of the long-
term outcome related to a variety of the malformations
have recently been published—on ocular problems [10],
speech pathology [11], oral health including teeth [12] and
the development of degenerative changes to the lower
limbs and the cervical spine [13, 14]. Studies from Japan
report that mental health had deteriorated and anxiety
levels had increased in this population [15].
To date, there has been no published study on the effect
of such extremity malformations on the health-related
quality of life (HRQL). Knowledge relating to this specific
long-term outcome would help to guide medical profes-
sionals on how to care for younger individuals with these
types of extremity malformation, regardless of origin, and
also help to predict the need for future assistance.
Instruments for the evaluation of HRQL are currently
being used to describe different aspects of daily life. These
instruments measure both the mental and the physical
components of HRQL. However, to evaluate functions in a
specific condition or disease, specific questionnaires are
usually used. Malformations of the extremities, like those
in TE, might affect daily living and thereby also HRQL. It
is therefore of great interest to evaluate the function of the
upper and the lower extremities using specific instruments.
The aim of this study was to evaluate HRQL in middle-
aged individuals with TE using the following specific
research questions: (1) Is the HRQL in middle-aged indi-
viduals with TE similar to that of the general population?
(2) To what extent do limb malformations affect HRQL?
(3) Does the function of the upper or the lower limbs, as
measured by validated disease-specific questionnaires,
correlate to general HRQL?
Materials and methods
Study design
The National Thalidomide Society was established during
the 1960s when legal processes against the manufacturing
company began. It includes all individuals who have been
diagnosed with TE according to the described standards
[16–18]. All individuals, apart from 24 individuals who had
refused contact for any study purpose, were invited to
participate in this study. Eighteen individuals refused to
participate, 33 did not respond to the invitation, and 33 did
accept the invitation to participate. Among these latter 22
individuals, two patients were not included in the study due
to severe neurological disability (n = 1) and recent stroke
just before the examination (n = 1). As a result, 31 indi-
viduals were enrolled in the study.
The study was multidisciplinary and, in addition to the
orthopedic assessment, we included ophthalmology, oto-
laryngology, speech pathology, dentistry, and neuropsy-
chiatry investigations. Individuals underwent a full clinical
examination, a spiral computed tomography scan of the
lower limbs, and an magnetic resonance imaging study of
the cervical spine for the evaluation of existing malfor-
mations and the development of degenerative changes.
Detailed descriptions of these findings have been published
[13, 14].
Study group–baseline data
The median age at follow-up was 46 (range
(45.2–50.1)years, and 13 (42%) were female. Basic infor-
mation relating to the malformations of the patients is given
in Table 1. Twenty-seven individuals (87%) had malfor-
mations of the upper limbs and 25 (81%) had malformations
of the hand(s). All but one individual had two existing hands
with at least three fingers on each. Significant arm shortening
was present in four individuals. Some grip function was
found bilaterally in 27 individuals, but only 11 of these had a
proper bilateral anatomical pincer grasp. Three individuals
(10%) used orthotic devices of the upper limbs.
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Few individuals had severe malformations of the lower
limbs; five had a proximal focal femoral deficiency, PFFD
[19, 20], which was bilateral in three of these individuals
(Table 2; Fig. 1). Four of the five also had major lower leg
malformations, such as tibia or fibular hypoplasia or
aplasia. One lower limb had a normal anatomy, including
the foot, but all of the lower limbs showed some type of
foot deformity. No individual had undergone a Van Ness
rotation plasty [21], reconstructive surgery, or lengthening
procedures, but six other surgical procedures had been
performed in this group. All individuals had a significant
shortening of the lower limb(s), necessitating the use of
prostheses and occasionally a wheelchair in four individ-
uals (13% of the study group). All five patients with PFFD
had several malformations of the upper extremities. The
five individuals with PFFD were compared with the rest of
the group (n = 26).
For the purpose of this study, major malformations that
were expected potentially to affect the function and/or
quality of life (QoL) were used as a basis for evaluations.
These major malformations included considerable short-
ening or deformity and/or severe functional loss. The latter
was defined as a lack of proper gripping function in the
upper extremity and/or as having difficulties with loco-
motion or positioning of the body to reach out due to
shortening or deformity/ies of the lower extremities. Six-
teen individuals had no major deformities of any of the four
extremities, while 15 had major deformities affecting
function in at least one extremity (one extremity in five
individuals, two in nine individuals and four extremities in
one individual).
Questionnaires
In order to identify the impact of the condition and the
individual disability, we used a number of generic and
specific quality-of-life questionnaires. All the question-
naires have been validated previously and used for their
specific purposes. A standardized procedure for question-
naire administration was followed [22]. All questionnaires
Table 1 Muskuloskeletal malformations found in 31 individuals with thalidomide embryopathy at follow-up of this study
Upper extremity n (%) Lower extremity n (%) Other malformations n (%)
At any location of the upper extremity 27 (87) PFFD in combination with other deformitiesa 5 (16) Ear: hearing deficit 6 (19)
Shoulder 5 (16) Hip deformity without a diagnosis of PFFDb 1 (3) Facial nerve palsy 3 (10)
Elbow/forearm 11 (36) Other malformations Duane’s syndromec 9 (29)
Hand 25 (81) Incomitant gaze 10 (32)
Type of grip function Tearing while eating 5 (16)
Anatomical pincer grip bilaterally 11 (36) Other internal anomaliesd 10 (32)
Any type of functional grip bilaterally 27 (87)
All values in table represent occurrence in number of patients, regardless of whether it is uni- or bilateral
PFFD Proximal focal femoral deficiency
a See Table 2 for further description
b Dislocated hip, coxa vara, and femoral bowing before surgery with total hip replacement. The primary appearance is unknown
c Duane’s syndrome; a disorder in abduction of the eyes due to defect cranial nerve 6 (CN)
d Includes double vagina, aplasia of the uterus, kidney aplasia, choanal atresia and enamel hypoplasia
Fig. 1 Computed tomography scan of one study participant with
bilateral proximal focal femoral deficiency and fibular hypoplasia and
tibial aplasia of the lower limbs
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were completed on the same occasion during a personal
visit and prior to the clinical examination.
Sociodemographic issues were covered by questions
relating to family situation, working conditions, and gen-
eral health issues, including other diseases, pain, and
medication.
Functional analysis
Function of the limbs was evaluated by specific question-
naires. The Disorder in Arm, Shoulder and Hand (DASH)
scale was used to evaluate the upper extremity function
[23, 24]. The results are presented as a disability/symptom
score (the DASH score) for all 30 essential items and as
two optional high performance scores, the Sport/Music and
Work scales, each comprising four items. The score ranges
from 1 (no difficulty performing an activity) to 5 (impos-
sible to perform), and at least 27 of 30 questions must be
answered. The results vary from 0 (best function, i.e., least
disability) to 100 (greatest disability).
The Rheumatoid Arthritis Outcome Score (RAOS) [25]
was used to evaluate the function of the lower extremities.
Five separate patient-relevant dimensions, namely, pain,
other symptoms (i.e., stiffness, swelling, and range of
motion), activities of daily living (ADL), sport and recre-
ational (Sport/Rec), and lower limb-related QoL are cal-
culated after answering the self-administered 42-item
questionnaire. Each item is graded as no, mild, moderate,
severe, and extreme (scored as 0–4), and each of the five
subscale scores are then calculated as the sum of the items
included. Raw scores are transformed to a zero to 100
(worst to best) scale.
The DASH disability/symptoms score and the pain score
of the RAOS were included in the correlation analyses.
General HRQL
General HRQL was evaluated using the 36-Item Short
Form Health Survey (SF-36) questionnaire. The eight
subscales and the Physical and Mental Composite
Table 3 Sociodemographic variables reported by 31 individuals with thalidomide embryopathy
Sociodemographic variables All patients (n = 31) Occurrence of major malformations in any of the limbs
No (n = 16) Yes (n = 15) p value
Family situation
Marital status
Never married 5 (16) 2 (13) 3 (20) 0.55 ns
Married/cohabitant 25 (81) 13 (81) 12 (80)
Divorced/widowed 1 (3) 1 (6) 0
No of individuals without children 9 (29) 5 (31) 4 (27) 0.89 ns
Education (highest achieved level)
\7 years of school attendance 0 0 0 0.69 ns
High school (completed or not) 4 (13) 3 (19) 1 (7)
Vocational school 3 (10) 1 (6) 2 (13)
College (completed or not) 15 (48) 8 (50) 7 (47)
Graduate school 9 (29) 4 (25) 5 (33)
Working life
Employment
Currently working 24 (77) 13 (81) 11 (73) 0.41 ns
Housewife 1 (3) 1 (6) 0
Sick listed or retired 6 (19) 2 (13) 4 (27)
Working time
Working full time (of those working) 15 (62) 9 (69) 6 (55) 0.32 ns
Stress
No stress 7 (23) 3 (19) 4 (27) 0.47 ns
Minor stress 23 (74) 13 (81) 10 (67)
Heavy stress 1 (3) 0 1 (7)
Values in table are given as the number of patients with the percentage of the group under consideration given in parenthesis
ns Not significant
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Summary scores were calculated, resulting in 100 as the
best possible score for the subscores and 50 as the norm for
the composite scores. The SF-36 has been psychometri-
cally well documented, as well as previously validated for
use in our country [26]. The results are presented as the
mean and 95% confidence interval (CI).
For the evaluation of the reported level of QoL as
measured by the SF-36, the patients’ results were compared
with the national norms, i.e., the general population. An
individual z-score for each subscale of the individual par-
ticipants in the study was calculated. In this analysis, the
reference values, mean, and standard deviation (SD) for all
subscales are first identified for the gender and 5-year age
interval in the national SF-36 reference population that
corresponds to the specific individual. Thereafter, the dif-
ference between the individual domain score value and the
reference mean for that specific subscale is calculated. This
difference is then divided by the reference SD. As a result,
each subscale of the SF-36 for that particular individual
receives its own z-score, which therefore reflects the dif-
ference for that specific individual compared with the
normal population. These z scores were used for statistical
calculations.
Further, the EuroQ Five Dimensions health question-
naire (EQ-5D) was also used to evaluate the general HRQL
[27]. Validation for use in our country has been performed
[28]. The results for this study group were compared with
the results for the general population from the age group
equivalent to the study group (age 40–49 years) [29].
Statistical methods
The results relating to continuous variables as well as to
changes in continuous variables were described with
number (n), mean, SD, and range for each group. The
results of the SF-36 were presented as the mean with the
95% confidence interval, while those of the EQ-5D were
presented as the mean with the standard error, according to
the most used standards for these questionnaires. The
results for categorical variables, including dichotomous
variables, were presented as a number and percentage.
Table 4 Function of the lower extremity as measured by the
Rheumatoid Arthritis Outcome Score in individuals with thalidomide
embryopathy
Patient-relevant dimensions of RAOS Individuals with TEa
Pain 78.5 (20.6) [36–100]
Symptoms 78.6 (17.9) [32–100]
Activities of daily life 83.1 (19.7) [40–100]
Sports and recreation 61.9 (36.4) [0–100]
Quality of life 66.1 (26.2) [19–100]
Values are presented as the mean score with the standard deviation in
parenthesis and the range in square brackets. 100 is the best possible
score.
RAOS Rheumatoid Arthritis Outcome Score, TE thalidomide
embryopathy
a Data were available for 31 individuals in each dimension, with the
exception of Activities of daily life for which data are available for 30
individuals
Fig. 2 Results for the five subscales/dimensions of the Rheumatoid
Arthritis Outcome Score (RAOS) in individuals with (n = 5, red) or
without proximal focal femoral deficiency (n = 26, blue). RAOS
subscales are: pain, other symptoms (i.e., stiffness, swelling, and
range of motion; Symptoms), activities of daily living (ADL), sport
and recreational (Sport), and lower limb-related quality of life (QoL)
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The Mann–Whitney U test was used to compare
continuous variables between two groups, and Fisher’s
exact test was used to compare dichotomous variables
between two groups. The Mantel–Haenszel v2 test was
used for comparisons between two groups involving
ordered categorical variables, and the v2 test was used
to compare groups involving non-ordered categorical
variables. Correlations were analyzed with Spearman’s
rank correlation. All tests were two-tailed and con-
ducted at the 5% significance level. Wilcoxon signed-
rank test was used when comparing two related
samples.
Fig. 3 Physical Composite Scores of the 36-Item Short Form Health
Survey (SF-36) in the entire study group and analyses of the
subgroups. Summary scores of 50 represent a level regarded as
normal (national norm). Comparisons in relation to national norms (z-
scores): *p\0.05, **p\ 0.01 (red color, located just above the
respective bar). Comparisons between groups: *p\0.05, **p\ 0.01
(blue color, located at the top of the figure). PFFD Proximal focal
femoral deficiency
Fig. 4 Subscores of the SF-36
for the total study group and for
subgroups in terms of the
occurrence of major
malformations of the
extremities or of PFFD. The
results for the general national
reference population adjusted
for age and gender are also
presented for reference
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Statistical analyses were performed using version 9 of
the SAS System for Windows (SAS Institute, Cary, NC)
and version 19 of the Statistical Package for the Social
Sciences (SPSS; IBM Corp., Armonk, NY).
Results
Sociodemographic data
Sociodemographic conditions are presented in Table 3.
Twenty-four individuals (77%) were working at the time of
the study, of whom 15 (15/31, 60%) worked full time.
Despite major limb deformities, only four of 15 (27%)
individuals were sick listed or retired. Only one individual,
with major limb malformations, reported a living situation
with heavy stress. Ten individuals reported the daily use of
analgesics. The group with major limb deformity/ies did
not differ from those without any major limb malforma-
tions for any of the variables listed in Table 3.
Function of the upper and lower limbs, i.e., disease-
specific HRQL
Upper extremities
The DASH disability/symptoms score, which evaluates the
function of the upper extremities, was 20.5 (SD 15.6) for
the entire study group. Significantly reduced upper
extremity function was noted in the group with major limb
Table 5 Health-related quality of life as measured by the EuroQ Five Dimensions health questionnaire in patients with thalidomide
embryopathy
HRQL dimensions Entire study
group (n = 31)
Occurrence of PFFD National
populationa
No (n = 26) Yes (n = 5) p value
Health profile
Mobilityb 0.018
I have no problems walking about 24 (80.0%) 23 (88.5%) 1 (25.0%) 94%
I have some problems walking about 6 (20.0%) 3 (11.5%) 3 (75.0%) 6%
I am confined to bed 0 (0.0%) 0 (0.0%) 0 (0.0%)
Self-care 1.00 ns
I have no problems with self-care 28 (90.3%) 24 (92.3%) 4 (80.0%) 98.5%
I have some problems washing or dressing myself 2 (6.5%) 1 (3.8%) 1 (20.0%) 1.5%
I am unable to wash or dress myself 1 (3.2%) 1 (3.8%) 0 (0.0%)
Usual activities 0.0098
I have no problems performing my usual activities 23 (74.2%) 22 (84.6%) 1 (20.0%) 91.5%
I have some problems performing my usual activities 8 (25.8%) 4 (15.4%) 4 (80.0%) 8.2%
I am unable to perform my usual activities 0 (0.0%) 0 (0.0%) 0 (0.0%)
Pain/discomfort 0.14 ns
I have no pain/discomfort 5 (16.1%) 5 (19.2%) 0 (0.0%) 61.1%
I have moderate pain/discomfort 17 (54.8%) 15 (57.7%) 2 (40.0%) 38.9%
I have extreme pain/discomfort 9 (29.0%) 6 (23.1%) 3 (60.0%)
Anxiety/depression 0.29 ns
I am not anxious or depressed 22 (71.0%) 17 (65.4%) 5 (100.0%) 73.9%
I am moderately anxious or depressed 9 (29.0%) 9 (34.6%) 0 (0.0%) 26.1%
I am extremely anxious or depressed 0 (0.0%) 0 (0.0%) 0 (0.0%)
EQ-5D Index 0.61 (0.12) 0.66 (0.12) 0.31 (0.41) 0.035
EQ VAS rating 69 (3.0) 69.8 (7.1) 65.4 (3.4) 0.61 ns
Values in table are presented as a number of patients with the percentage for that group in parenthesis or as the mean values with the standard
error in parenthesis, as appropriate
EQ-5D EuroQ Five Dimensions health questionnaire, VAS visual analog scale
a n = 30
b According to Burstrom et al. [29]
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deformity/ies (mean 25.3, SD 17.3) compared with those
without any major limb deformities (mean 14.3, SD 12.1;
p = 0.015). Likewise, the group with PFFD had a signifi-
cantly reduced upper extremity function (mean 34.3, SD
6.3) compared with those without PFFD (mean 17.9, SD
15.5; p = 0.0040). The more detailed scores for work and
for sports/music did not reveal any differences between the
subgroups.
Lower extremities
The function of the lower limbs, as measured by the RAOS
is presented in Table 4. The RAOS was not affected by the
occurrence of major limb deformity/ies, but the group with
PFFD had significantly reduced function based on the
scores for ADL, sports and recreation (Sport/Rec), and
lower limb-related QoL compared with those without
PFFD (Fig. 2).
QoL as determined using generic questionnaires
Physical and mental composite scores of SF-36
The physical composite summary score for the entire group
(mean 40.6, 95% CI 35.4–45.8) was significantly reduced
in relation to the national norm (population-based control
group) (Fig. 3). Individuals with limb/limbs with major
deformity/ies had a significantly lower physical HRQL as
measured by the Physical Composite Score (PCS) of the
SF-36 compared with those without any extremities with
major deformities (mean 34.6 vs. 45.8, respectively;
p = 0.040). The group with PFFD also reported a signifi-
cant reduction in the PCS compared with the rest of the
group (mean 18.3, vs. 44.0, respectively; p = 0.00031).
The mean Mental Composite Score was 51.5 (95% CI
47.1–56.0) for the entire study group and no differences
were noted between the subgroups. Also, no differences
were found in the z-score analyses in relation to the control
group for the entire study group or the subgroups.
SF-36 subscores
The outcome as HRQL as measured by the SF-36 is shown
in Fig. 4. The entire study group reported low levels for
physical QoL, with scores for the Physical (mean 65.3,
95% CI 51.4–79.3), Bodily Pain (mean 54.6, 95% CI
44.6–64.5), and General Health (mean 60.9, 95% CI
53.0–68.7) dimensions all significantly lower than those of
the population-based control group. The mean Vitality
dimension score was 59.2 (95% CI 51.4–67.0) for the total
study group, which was also significantly lower than that of
the population-based control group.
Individuals with and without major limb deformity/ies
did not differ significantly from one another for any of the
subscores. The z-score analysis revealed that the physical
subscales and Vitality score of the group with major
deformities were significantly different those of the general
population. The mental subscales did not differ signifi-
cantly between the subgroups or in relation to the healthy
population.
The individuals with PFFD (n = 5) had a significantly
poorer physical QoL than those without PFFD (n = 26),
with the former having a lower mean Physical Functioning
score [12.5 (95% CI -6.4 to 31.4) vs. 82.9 (95% CI
75.1–90.7)] and a lower mean score for Bodily Pain [33.6
(95% CI 18.0–49.2 vs. 58.6 (95% CI 47.5–69.7);
p = 0.044]. The group without PFFD had significantly
lower z-scores for Bodily Pain, General Health, and
Vitality than did the general population. In the group with
PFFD, the mean z-score for Physical Functioning was
-4.2, which is fourfold lower than the standard deviation
for the general population, but this difference was not
statistically significant. For the mental subscales, no sig-
nificant differences were noted between the two subgroups
Table 6 Correlation analyses between health-related quality of life and functional scores in patients with thalidomide embryopathy according to
Spearman’s rank correlation test
Generic questionnaires on HRQL DASH ground score RAOS pain Number of extremities with major
malformations (0–4)
SF-36
Physical composite summary score -0.72 (p\ 0.0001) 0.53 (p = 0.0028) -0.3 ( p = 0.035)
Mental composite summary score 0.17 ns (p = 0.36) 0.056 ns (p = 0.77) 0.085 ns (p = 0.66)
EQ-5D
Aggregated score -0.74 (p\ 0.0001) 0.61 (p = 0.0003) -0.18 ns (p = 0.33)
Health state today 0.15 ns (p = 0.41) 0.075 ns (p = 0.69) -0.087 ns (p = 0.64)
SF-36 36-Item Short Form Health Survey
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or when the subgroups were compared with the general
population.
EQ-5D instrument
Table 5 shows the results of the EQ-5D analyses. The five
dimensions of the EQ-5D were not affected by the presence
of extremities with major deformities. The EQ-5D index
was significantly lower in the group of individuals with
PFFD than in those without (mean 0.35 vs. 0.66;
p = 0.035). Moreover, for the Mobility and the Usual
Activities subscales, a similar difference was observed.
Correlations between limb function and HRQL
The results from the correlation analyses are shown in
Table 6. The physical QoL (as expressed by the SF-36
physical composite summary score) was found to correlate
with the upper extremity function, as expressed by the
DASH disability/symptoms score (rs = -0.73,
p\ 0.0001), with the RAOS pain score for the lower
extremities (rs = 0.53, p = 0.0028) and with the number
of extremities (rs = -0.39, p = 0.035).
The aggregated score of the EQ-5D also correlated
strongly with both the DASH Disability/Symptoms score
and the RAOS Pain score.
Discussion
To our knowledge, this study is the first long-term follow-
up of HRQL in relation to limb deformities in individuals
with TE. The main finding of our study is that the physical
aspects of HRQL in many of these individuals were sig-
nificantly lower than those of the national reference pop-
ulation, but that the mental aspects of HRQL were not
significantly affected. The physical aspects of HRQL were
found to correlate with the severity of the malformations.
None of the individuals participating in this study had
undergone the type of reconstructive surgery of the lower
limbs which corrected for differences in limb length or
relocated/stabilized the hip, knee, or ankle joint(s); con-
sequently, the study group can be regarded as ‘‘untreated’’.
The results can therefore be seen as the natural history of
these individuals and be used for a comparison of the
outcome of current treatment strategies for lower limb
malformations.
One important aspect of HRQL is whether differences
occur in the study population in relation to the general
population and to what extent. We used the SF-36 as the
primary instrument to evaluate general HRQL as we had
the opportunity to compare the study group and the
national reference population using calculated z-scores.
Compared to the national reference population, both the
entire group and the subgroup with major limb deformities
(according to either the number of limbs affected or the
existence of severe lower limb malformations) had signif-
icantly reduced scores for the physical aspects of QoL. The
subgroup with the lowest score for the physical aspects was
the PFFD group, with a Physical Functioning score of only
12.5 compared with 88.6 in the reference population;
however, this difference was not found to be significantly
lower, despite being at a level of 4.3 SD below the refer-
ence population. The reason why such a large difference
was not found to be significant can be explained by the fact
that a comparison with a subgroup of only five individuals
does not have the statistical potential to reveal these dif-
ferences, even though they might truly exist. It is note-
worthy that all of the differences observed between the TE
group and the national reference group were above what
has been considered to be a threshold for a clinically
meaningful difference (6–8 points) [30].
The results of the EQ-5D from the general national
population, presented as the percentage of individuals who
reported moderate or severe problems, were used for
comparison [29]. All dimensions involving physical
activities revealed a lower level of HRQL, while the mental
aspect (anxiety/depression) was unaffected, similar to the
results found for the SF-36.
Two previous studies have reported results similar to
ours for HRQL in individuals with TE. In 2002, Nippert
et al. presented a report stating that 166 women with TE,
aged 38 years, had significantly reduced physical QoL, as
measured by the World Health Organization QOL-BREF
instrument, but no reduction in psychological well-being
[31]. Bent et al. reported that 41 individuals with TE, aged
40 years, had a physical function, as measured by the
subscores of the SF-36, lower than their normative scores
for the age group and that this was especially evident in
individuals with a higher degree of perceived disability
[32].
Interestingly, the mental aspects of QoL were not
affected in the TE group participating in our study. This
result may indicate that despite significant physical limi-
tations in some cases, an acceptable level of mental well-
being had been achieved, i.e., at a level similar to that of
the rest of the national population. One possible expla-
nation for this result may be that children who are born
with congenital malformations do not know anything but
the situation they have and have therefore adapted to it.
Another contributory factor might be the support which
society gives to TE individuals. When it was ultimately
concluded that the malformations were caused by
thalidomide, legal actions started against the distributing
medical company and the National Thalidomide Society
was set up. This resulted in the affected individuals not
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only receiving financial compensation, but also the
attention and support of society in large. Since then, the
Society has taken care of the interests of the group at all
levels. In addition, it is possible that only individuals who
had an acceptable mental HRQL may have chosen to
participate in the study, which might have skewed the
results towards a better outcome. A recent Japanese study
[15] reported on 22 patients with TE and reported that
59% were assessed as having some kind of mental health
problems. As this study focused solely on psychological
and mental health problems, it used methods that were
more specifically directed towards mental well-being and
therefore more sensitive to the mental state than the rel-
atively rough methods used in our study, which covers
both mental and physical aspects. However neither the
Japanese study nor our study reflects an entire national
population with TE and in order to evaluate the true
incidence of mental health problems, further studies will
be needed. However, even if the present study does not
reflect the true spectrum of mental well-being in the total
TE population, it is still possible to use the results to
evaluate the effects of limb malformations on mental
well-being. Our results clearly show that despite a situa-
tion with reduced physical ability due to multiple mal-
formations, it is possible to acquire a level of mental
HRQL that is similar to that of the general population.
Other important aspects of QoL are the sociodemo-
graphic circumstances in which people live. The family
situation and working conditions of our study group did not
differ from those of general situation in Sweden. The study
by Nippert et al. [31] reported rates of marriage/child-
lessness in the TE population as 42/63% and, in 2007, Bent
[32] reported respective values of 70/46%, compared with
our study results of 81/29%. More specifically, for working
conditions, Nippert et al. [31] reported that 60% of the TE
population were in full employment and 27% had retired,
compared with our results of 48 and 19%, respectively. In
terms of the reported stress levels, comparisons were more
difficult, as this requires a more detailed discussion.
However, the most important finding is that the occurrence
of major deformities did not appear to impose any increase
in stress on these individuals.
One limitation of our study is that other malformations
or problems associated with TE, except for the limb
deformities, might also affect HRQL. We therefore sear-
ched the results from the other parts of this multidisci-
plinary study in order to identify these factors. Duane’s
syndrome was presented in 11 of 29 of the individuals
examined in our study group, but they were found to be
relatively mild and would therefore not affect the HRQL
[10]. We therefore regarded the possible effect of such
malformations on the level of QoL to be minimal and
refrained from including this aspect in the analyses.
This study does not include the entire national popula-
tion of individuals with TE. We do not know the incidence
of malformations among those individuals with TE who
did not participate, and this information has never been
collected. The individuals who participated in our study do,
however, present the full spectrum of malformations, and
we were therefore able to analyze the effect of limb mal-
formations on function and HRQL. As studies related to
limb malformations and their consequences for the indi-
vidual in the long term have not been published, we felt it
was extremely important to present these findings. The
results for the group of five individuals with PFFD, who
were virtually untreated compared with current strategies
involving extensive reconstructive surgery, can be regarded
as natural history.
Taken together, the physical limitations significantly
affected the physical HRQL in many individuals. No
individual in our group of individuals with TE had received
any reconstructive surgery of the lower extremities.
Despite these physical limitations, most individuals
actively participated in society, and their mental HRQL
was at the same level as that of the general population. One
possible explanation for this result is the major support
received by these individuals from society, which includes
financial compensation, obtained after the initial legal
processes, and/or continued societal compensation when
needed, as well as physical and psychological support,
given by the families, environment and the national asso-
ciation. Modernized treatment strategies for orthopedic
lower limb manifestations will help improve physical
function in the future. Ackerman et al. reported on 12
individuals with PFFD only who were followed for a mean
of 21 years after surgery with Van Nes rotation plasty
performed at a mean age of 6.5 years. These authors
reported physical function on the SF-36 that was similar to
that of a collected age- and gender-matched control group,
despite significant physical limitations among these 12
individuals [21]. Thus, with the improved treatment
strategies for PFFD and tibia/fibula hypoplasia that are now
available, which result in improved stability of the joints,
reductions in limb length inequality, and less need for
orthotic devices, physical function can be expected to
improve substantially. This will hopefully further improve
the physical long-term outcome for children who are born
today with severe limb malformations or with TE.
Preventing the birth of children with TE is therefore
crucial. Thalidomide is currently being used, seemingly
with inadequate information on the well-known teratogenic
properties, as children with TE are still being born today.
Those responsible for treatment with thalidomide today
must actively reduce the number of affected children, and
if a child with TE is born despite these efforts, modern and
continuous care and treatment must be ensured in order to
J Child Orthop (2016) 10:691–703 701
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achieve an acceptable level of QoL, both health-related as
well as socioeconomic, throughout his/her lifetime. If these
measures cannot be ensured, the continued use of
thalidomide is truly unethical.
Conclusions
The conclusions of the present follow-up at early middle
age in this study group of individuals with TE are as
follows.
1. The physical HRQL was significantly negatively
affected in many individuals and correlated well with
the existence of major limb deformities or with
reduced function of the upper and lower extremities.
2. Despite overall affected HRQL, the mental aspects of
QoL were not affected.
3. The majority of the middle-aged TE individuals were
working, had a family, and did not experience large-
scale stress.
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